Assessing B-cell depletion and disease activity in a french multiple sclerosis cohort treated by long-term anti-CD20 antibody therapy

被引：0
|
作者：
Freeman, S. [1 ]
Lemarchant, B. [1 ,2 ]
Alberto, T. [1 ]
Drelon, A. [1 ]
Boucher, J. [1 ]
Dubucquoi, S. [3 ]
Zephir, H. [1 ,2 ]
机构：
[1] Univ Lille, Dept Neurol, CRC SEP, CHU Lille, Lille, France
[2] Univ Lille, INSERM, CHU Lille, Lille, France
[3] Univ Lille, INSERM, CHU Lille, U1286,INFINITE Institute Translat Res Inflammat, Lille, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P328
引用
收藏
页码：355 / 356
页数：2
相关论文
共 50 条
  • [41] B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies
    Leandro, Maria J.
    ARTHRITIS RESEARCH & THERAPY, 2013, 15
  • [42] Quality of life in patients with B-cell lymphoma during maintenance therapy with the Anti-CD20 antibody rituximab
    Witzens-Harig, Mathias
    Heiss, Christiane
    Benner, Axel
    Hensel, Manfred
    Neben, Kai
    Dreger, Peter
    Kraemer, Alwin
    Ho, Anthony D.
    BLOOD, 2007, 110 (11) : 189B - 189B
  • [43] Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis
    Roccatello, D
    Baldovino, S
    Rossi, D
    Mansouri, M
    Naretto, C
    Gennaro, M
    Cavallo, R
    Alpa, M
    Costanzo, P
    Giachino, O
    Mazzucco, G
    Sena, LM
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (12) : 3054 - 3061
  • [44] Construction and Characterization of a Bispecific Anti-CD20 Antibody with Potent Antitumor Activity against B-Cell Lymphoma
    Li, Bohua
    Zhang, Xunming
    Shi, Shu
    Zhao, Lei
    Zhang, Dapeng
    Qian, Weizhu
    Zheng, Lei
    Gao, Jie
    Wang, Hao
    Guo, Yajun
    CANCER RESEARCH, 2010, 70 (15) : 6293 - 6302
  • [45] Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series
    Øystein Fluge
    Olav Mella
    BMC Neurology, 9
  • [46] Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series
    Fluge, Oystein
    Mella, Olav
    BMC NEUROLOGY, 2009, 9
  • [47] Effect of Subcutaneous Treatment With Anti-CD20 Antibody on B-cell Depletion in a Lipopolysaccharide-Induced Inflammatory Mouse Model
    Dawson, Janet
    Touil, Ismahane
    Scheidegger, Anja
    Vogelsanger, Melanie
    Leppert, David
    Weckbecker, Gisbert
    NEUROLOGY, 2019, 92 (15)
  • [48] Influence of Body Mass Index on B Lymphocyte Repopulation in Multiple Sclerosis Patients Treated with Anti-CD20 Therapy
    Loeffler, Jacob
    Han, May
    NEUROLOGY, 2023, 100 (17)
  • [49] B Cell Targeting Therapy Using the Anti-CD20 Antibody in Autoimmune Diseases
    Tanaka, Yoshiya
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2009, 129 (06): : 675 - 679
  • [50] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    R Eisenberg
    D Albert
    J Stansberry
    D Tsai
    S Kolasinski
    S Khan
    Arthritis Res Ther, 5
12345